

Cover Story
Free
By Matthew Bin Han Ong
FDA's passive reliance on self-reporting by hospitals and device manufacturers allowed harm caused by power morcellators to go unnoticed for over two decades—likely contributing to injury and deaths of hundreds of women, according to the U.S. Government Accountability Office said.
In Brief
Funding Opportunities
Drugs & Targets
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”
- Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again)
- One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- As more people are surviving cancer, we must continue funding bold science
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis















